Drugs / CST-2032
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05033912 | Oct 2021 → Mar 2022 | Parkinson disease, cognitive disorder | CuraSen Therapeutics, Inc. | Withdrawn | No outcome recorded Stop: Business |
| Phase 21 trial | ||||||
| Phase 2 | NCT05104463 | Apr 2022 → Dec 2023 | cognitive impairment with or without cerebellar ataxia, dementia | CuraSen Therapeutics, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-03-07 | CuraSen Therapeutics, Inc. | Results CuraSen Therapeutics Announces Oral Presentation of Additional Positive Phase 2a Data with CST-2032/CST-107 in Patients with Alzheimer’s or Parkinson’s Disease at AD/PD™ 2024 International Conference curasen.com ↗ |
| 2023-03-30 | CuraSen Therapeutics, Inc. | Results CuraSen Therapeutics to Present Phase 2 Data Showing Rapid-Onset Cognition and Mood Benefit with CST-103/CST-107 (Clenbuterol/Nadolol) in Parkinson’s Disease at the Alzheimer’s Disease and Parkinson’s Disease (AD/PD’23) Conference curasen.com ↗
Additionally, the company will present promising Phase 1 data with a second program, CST-2032/CST-107, in healthy participants and patients with mild cognitive impairment (MCI). |
All press releases naming this drug 4 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CST-2032 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05104463 ↗ |
| Route | Oral | “CST-2032 and matching placebo oral liquid” NCT05033912 ↗ |